Return to: Pediatrics : Medical School : Academic Health Center : myU : U of M Home

Gold University of Minnesota M. Skip to main content. Link to University of Minnesota homepage
Pediatrics Blood and Marrow Transplantation
Whats Inside
For Patients and Families

Research

Education

Faculty and Staff

News & Events

Contact Us

 

Peds BMT Home




University Pediatrics Foundation - Make a Gift

Viking Children's Fund

Children's Cancer Research Fund

Home > Department of Pediatrics > Blood and Marrow Transplantation > Faculty and Staff > Michael Verneris, M.D.

Printer-friendly version   Mail this page to a friend

Michael Verneris, M.D.


Dr. Michael Verneris

Assistant Professor
Mayo Mail Code 366
420 Delaware St. SE
Minneapolis, MN 55455
Phone: (612) 626-2961
Fax: (612) 626-4074
verneris@umn.edu
Preferred method of contact: Phone

Dr. Verneris is an Assistant Professor of Pediatrics, Division of Hematology-Oncology and Blood and Marrow Transplantation, and the Cancer Center. His clinical interests include hematopoietic cell transplantation for acute leukemias, prevention of graft-versus-host disease and graft-versus-leukemia.

He received his medical degree in 1992 from the Dartmouth-Brown Program in Medicine (Hanover, New Hampshire and Providence, Rhode Island). He completed his Pediatric Internship and Residency at Children's National Medical Center, Washington, D.C. His Pediatric Hematology/Oncology Fellowship was completed at the Lucile Salter Packard Children's Hospital at Stanford University, Palo Alto, California, where he was a staff physician from 1998-2002, prior to joining the faculty at the University of Minnesota. He is board certified in Pediatrics and Pediatric Hematology/Oncology.

Dr. Verneris's research interests include immunology, transplantation biology and therapy, and translational research. Areas of specific interest include NK cell development and activating and inhibitory NK receptors. Current laboratory efforts are focused on understanding the signaling pathways of a number of these receptors and how such pathways are influenced by allogeneic bone marrow transplantation and immunosuppressive medications. Other studies are aimed at enhancing NK cell responses to malignant diseases and adoptive transfer of NK cells to kill residual leukemia/cancer cells.

He serves on the University of Minnesota Institutional Biosafety Committee and the All-University Radiation Protection Advisory Committee. Dr. Verneris is a reviewer for nine scientific journals. He has been the recipient of numerous awards and is currently recipient of the Alexander Charles Jundt Research Award. Dr. Verneris is Principal Investigator on a number of grants, including two from the National Institutes of Health (K08-HL004505 and P30CA077598-07, pilot 19) and the Children's Oncology Group. He has 19 peer-reviewed publications.

Honors and Awards

  • 1999-2001 Fellow Scholar Award, American Society of Hematology
  • 2000 Honorable Mention, Young Investigator Award, American Society of Pediatric Hematology/Oncology
  • 2003 Charles Jundt Research Award, University of Minnesota

Research Interests

  1. Laboratory Based Research:
    • NK cell Development from Progenitor cells
    • Effect of Immune Suppressive Agents on NK cell Function
    • Role of Co-stimulatory Molecules on NK cell Function
  2. Translational Research:
    • Large Scale Expansion of NK cells and Adoptive Transfer following Allogeneic Hematopoietic Cell Transplantation
  3. Clinical Research:
    • Double Umbilical Cord Blood Transplantation for Relapsed and Refractory Acute Leukemias
    • Hematopoietic Cell Transplantation for Pediatric Solid Tumors

Selected Recent Publications

Grzywacz B, Kataria N, Sikora M, Oostendorp RA, Dzierzak EA, Blazar BR, Miller JS, Verneris MR. Coordinated acquisition of inhibitory and activating receptors and functional properties by developing human natural killer cells.  Blood. 2006 Aug 10

Kornacker M, Verneris MR, Kornacker B, Ganten TM, Schefford C, Negrin RS. The apoptotic and proliferative fate of cytokine-induced killer cells after redirection to tumor cells with bispecific Ab.  Cytotherapy. 2006;8:13-23.

Fraser CJ, Weigel BJ, Perentesis JP, Dusenbery KE, De For TE, Baker KS, Verneris MR. Autologous stem cell transplantation for high-risk Ewing's sarcoma and other pediatric solid tumors.  Bone Marrow Transplant. 2006;37:175-181.

Verneris MR, Arshi A, Kornacker M, Edinger M and Negrin RS. Low levels of Her2/neu expressed by Ewing's family tumor cell lines can redirect cytokine-induced killer cells.  Clin Cancer Res. 2005;11:4561-4570.

Peters A, Manivel JC, Dolan M, Gulbahce EH, Baker KS, Verneris MR. Pulmonary cytolytic thrombi after allogeneic hematopoietic cell transplantation: a further histologic description.  Biol Blood Marrow Transplant. 2005;11:484-485.

Verneris MR, Karami M, Baker J, Jayaswal A, Negrin RS. Role of NKG2D signaling in the cytotoxicity of activated and expanded CD8+ T cells.  Blood. 2004 Apr 15;103(8):3065-72. Epub 2003 Nov 20.


Feedback | Notice of Privacy Practices


 
The University of Minnesota is an equal opportunity educator and employer.